CY1114000T1 - Σταθεροποιημενα διαλυματα τεριπαρατιδης - Google Patents
Σταθεροποιημενα διαλυματα τεριπαρατιδηςInfo
- Publication number
- CY1114000T1 CY1114000T1 CY20131100405T CY131100405T CY1114000T1 CY 1114000 T1 CY1114000 T1 CY 1114000T1 CY 20131100405 T CY20131100405 T CY 20131100405T CY 131100405 T CY131100405 T CY 131100405T CY 1114000 T1 CY1114000 T1 CY 1114000T1
- Authority
- CY
- Cyprus
- Prior art keywords
- stabilized
- parathyroid hormone
- buffer
- stabilized teriparatide
- solutions
- Prior art date
Links
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 title abstract 2
- 108010049264 Teriparatide Proteins 0.000 title 1
- 229960005460 teriparatide Drugs 0.000 title 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 abstract 3
- 102000003982 Parathyroid hormone Human genes 0.000 abstract 3
- 108090000445 Parathyroid hormone Proteins 0.000 abstract 3
- 239000000199 parathyroid hormone Substances 0.000 abstract 3
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 abstract 2
- 229960001319 parathyroid hormone Drugs 0.000 abstract 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 235000019445 benzyl alcohol Nutrition 0.000 abstract 1
- 239000000872 buffer Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 239000006174 pH buffer Substances 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920005862 polyol Polymers 0.000 abstract 1
- 150000003077 polyols Chemical class 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 229940095064 tartrate Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Silver Salt Photography Or Processing Solution Therefor (AREA)
Abstract
Περιγράφεται σταθεροποιημένη φαρμακευτική σύνθεση σε μορφή διαλύματος για παρεντερική χορήγηση παραθυρεοειδούς ορμόνης όπου το θεραπευτικά δραστικό συστατικό σταθεροποιείται με ρυθμιστικό διάλυμα και πολυόλη. Τα προτιμητέα παρασκευάσματα περιέχουν σε υδατικό διάλυμα ανθρώπινη ΡΤΗ(1-34) (παραθυρεοειδή ορμόνη), μαννιτόλη, ρυθμιστικό παράγοντα pΗ οξικού ή τρυγικού και m-κρεζόλη ή βενζυλική αλκοόλη ως συντηρητικό.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6907597P | 1997-12-09 | 1997-12-09 | |
EP03104219.5A EP1417972B2 (en) | 1997-12-09 | 1998-12-07 | Stabilized teriparatide solutions |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1114000T1 true CY1114000T1 (el) | 2016-07-27 |
Family
ID=22086574
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20131100405T CY1114000T1 (el) | 1997-12-09 | 2013-05-17 | Σταθεροποιημενα διαλυματα τεριπαρατιδης |
Country Status (32)
Country | Link |
---|---|
EP (2) | EP0920873B1 (el) |
JP (1) | JP4405666B2 (el) |
KR (1) | KR100482703B1 (el) |
CN (1) | CN1198644C (el) |
AR (1) | AR018526A1 (el) |
AT (1) | ATE260113T1 (el) |
AU (1) | AU759726B2 (el) |
BR (1) | BR9813463A (el) |
CA (1) | CA2314313C (el) |
CY (1) | CY1114000T1 (el) |
CZ (1) | CZ302401B6 (el) |
DE (1) | DE69821872T2 (el) |
DK (2) | DK0920873T3 (el) |
EA (1) | EA004761B1 (el) |
EG (1) | EG23675A (el) |
ES (2) | ES2215268T3 (el) |
HK (1) | HK1021798A1 (el) |
HU (1) | HU230784B1 (el) |
ID (1) | ID27741A (el) |
IL (1) | IL136662A (el) |
MY (1) | MY120063A (el) |
NO (1) | NO327302B1 (el) |
NZ (1) | NZ505222A (el) |
PE (1) | PE20000001A1 (el) |
PL (1) | PL194268B1 (el) |
PT (2) | PT920873E (el) |
SK (1) | SK288203B6 (el) |
TR (1) | TR200002134T2 (el) |
TW (1) | TW570811B (el) |
UA (1) | UA72884C2 (el) |
WO (1) | WO1999029337A1 (el) |
ZA (1) | ZA9811127B (el) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030166525A1 (en) | 1998-07-23 | 2003-09-04 | Hoffmann James Arthur | FSH Formulation |
PL346127A1 (en) * | 1998-07-23 | 2002-01-28 | Lilly Co Eli | Fsh and fsh variant formulations, products and methods |
AR033639A1 (es) | 1998-08-19 | 2004-01-07 | Lilly Co Eli | Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis |
US7022674B2 (en) | 1999-12-16 | 2006-04-04 | Eli Lilly And Company | Polypeptide compositions with improved stability |
CA2380423A1 (en) * | 2000-05-17 | 2001-11-22 | Bionebraska, Inc. | Peptide pharmaceutical formulations |
AU785444B2 (en) * | 2000-05-19 | 2007-06-14 | Jefferson Pharmaceuticals, Llc | Peptide pharmaceutical formulations |
EP1391209A4 (en) * | 2001-05-30 | 2009-12-16 | Chugai Pharmaceutical Co Ltd | PROTEIN PREPARATION |
WO2003039331A2 (en) * | 2001-11-05 | 2003-05-15 | Eli Lilly And Company | Method for improving stability of a bone-connecting implant |
EP1767213A3 (en) * | 2001-11-05 | 2007-04-25 | Eli Lilly & Company | Method for improving stability of a bone-connecting implant |
US8088734B2 (en) | 2003-01-21 | 2012-01-03 | Unigene Laboratories Inc. | Oral delivery of peptides |
KR101105486B1 (ko) | 2003-04-02 | 2012-01-13 | 아레스 트레이딩 에스.에이. | Fsh 및 lh과 비이온성 계면활성제의 액상 약제학적 제제 |
JP4871124B2 (ja) | 2003-06-20 | 2012-02-08 | アレス トレーディング ソシエテ アノニム | 凍結乾燥fsh/lh製剤 |
US7329725B1 (en) | 2003-10-29 | 2008-02-12 | Nastech Pharmaceutical Company Inc. | Phage displayed Trp cage ligands |
RU2421238C2 (ru) | 2003-11-20 | 2011-06-20 | Ново Нордиск А/С | Пептидная композиция, содержащая пропиленгликоль, являющаяся оптимальной для изготовления и применения в инъекционных устройствах |
RU2484086C9 (ru) | 2003-12-23 | 2013-08-20 | Инфинити Дискавэри, Инк. | Аналоги бензохинонсодержащих ансамицинов (варианты), способ их получения, фармацевтическая композиция (варианты) и способ лечения рака (варианты) |
US20060046962A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
EP1789075A4 (en) * | 2004-08-25 | 2009-07-01 | Uab Research Foundation | ABSORPTION ENHANCER FOR DRUG ADMINISTRATION |
US20140162965A1 (en) | 2004-08-25 | 2014-06-12 | Aegis Therapeutics, Inc. | Compositions for oral drug administration |
US8268791B2 (en) | 2004-08-25 | 2012-09-18 | Aegis Therapeutics, Llc. | Alkylglycoside compositions for drug administration |
US9895444B2 (en) | 2004-08-25 | 2018-02-20 | Aegis Therapeutics, Llc | Compositions for drug administration |
US9114069B2 (en) | 2004-08-25 | 2015-08-25 | Aegis Therapeutics, Llc | Antibacterial compositions for drug administration |
US8642564B2 (en) | 2004-08-25 | 2014-02-04 | Aegis Therapeutics, Llc | Compositions for drug administration |
KR100700869B1 (ko) * | 2005-06-03 | 2007-03-29 | 재단법인 목암생명공학연구소 | Pth, 완충제 및 안정제를 포함하는 안정한 pth조성물 |
WO2007059470A2 (en) | 2005-11-10 | 2007-05-24 | Board Of Control Of Michigan Technological University | Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
US8226949B2 (en) | 2006-06-23 | 2012-07-24 | Aegis Therapeutics Llc | Stabilizing alkylglycoside compositions and methods thereof |
USRE49444E1 (en) | 2006-10-03 | 2023-03-07 | Radius Health, Inc. | Method of treating osteoporosis comprising administration of PTHrP analog |
US7803770B2 (en) | 2006-10-03 | 2010-09-28 | Radius Health, Inc. | Method of treating osteoporosis comprising administration of PTHrP analog |
KR101512377B1 (ko) | 2006-10-03 | 2015-04-28 | 라디우스 헬쓰, 인코포레이티드 | 골 아나볼릭 단백질을 위한 약물 전달 방법 |
EP1958618A1 (de) * | 2007-02-15 | 2008-08-20 | Octapharma AG | Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren |
MX2009010808A (es) * | 2007-04-12 | 2009-10-29 | Infinity Discovery Inc | Formulaciones de ansamicina de hidroquinona. |
US20080299228A1 (en) * | 2007-05-29 | 2008-12-04 | Alan Gerald Harris | Topical compositions comprising a macromolecule and methods of using same |
EP2170268A2 (en) | 2007-06-25 | 2010-04-07 | Amgen, Inc. | Compositions of specific binding agents to hepatocyte growth factor |
AU2009228093B2 (en) | 2008-03-28 | 2014-08-07 | Neurelis, Inc. | Administration of benzodiazepine compositions |
WO2010045442A1 (en) | 2008-10-15 | 2010-04-22 | Infinity Discovery, Inc. | Ansamycin hydroquinone compositions |
US8440631B2 (en) | 2008-12-22 | 2013-05-14 | Aegis Therapeutics, Llc | Compositions for drug administration |
JPWO2011030774A1 (ja) * | 2009-09-09 | 2013-02-07 | 旭化成ファーマ株式会社 | 1回当たり100〜200単位のpthが週1回投与されることを特徴とする、pth含有骨粗鬆症治療/予防剤 |
JP2013512688A (ja) | 2009-12-07 | 2013-04-18 | ミシガン テクノロジカル ユニバーシティ | クロクマの副甲状腺ホルモン及びクロクマの副甲状腺ホルモンを使用する方法 |
ES2683902T3 (es) | 2011-06-14 | 2018-09-28 | Hale Biopharma Ventures, Llc | Administración de benzodiacepina |
CN102731643A (zh) * | 2012-06-26 | 2012-10-17 | 深圳翰宇药业股份有限公司 | 一种治疗骨质疏松多肽的制备方法 |
CN103301058A (zh) * | 2013-06-17 | 2013-09-18 | 深圳翰宇药业股份有限公司 | 一种特立帕肽注射用组合物及其制备方法和制剂 |
IL310069A (en) | 2015-04-29 | 2024-03-01 | Radius Pharmaceuticals Inc | Cancer treatment methods |
CN106309358A (zh) * | 2015-06-29 | 2017-01-11 | 成都金凯生物技术有限公司 | 含有人甲状旁腺激素的药物组合物及其制备方法与用途 |
JP6634758B2 (ja) * | 2015-09-25 | 2020-01-22 | ニプロ株式会社 | 液体組成物及び凍結乾燥製剤 |
JP7059195B2 (ja) | 2016-03-01 | 2022-04-25 | アセンディス ファーマ ボーン ディジージズ エー/エス | Pthプロドラッグ |
KR20240013849A (ko) | 2016-09-29 | 2024-01-30 | 아센디스 파마 본 디지즈 에이/에스 | 조절 방출 pth 화합물을 위한 투여 용법 |
KR20230170810A (ko) | 2016-09-29 | 2023-12-19 | 아센디스 파마 본 디지즈 에이/에스 | 낮은 피크 대 트로프 비를 가진 pth 화합물 |
WO2018129419A1 (en) | 2017-01-05 | 2018-07-12 | Radius Pharmaceuticals, Inc. | Polymorphic forms of rad1901-2hcl |
US10996208B2 (en) | 2017-04-28 | 2021-05-04 | Radius Health, Inc. | Abaloparatide formulations and methods of testing, storing, modifying, and using same |
PE20211202A1 (es) | 2017-08-24 | 2021-07-05 | Novo Nordisk As | Composiciones de glp-1 y sus usos |
JP2019060866A (ja) * | 2017-09-22 | 2019-04-18 | 旭化成ファーマ株式会社 | 液状医薬組成物の体内動態を予測する方法 |
CA3167644A1 (en) * | 2017-09-22 | 2019-03-28 | Asahi Kasei Pharma Corporation | Teriparatide-containing liquid pharmaceutical composition having excellent pharmacokinetics and/or safety |
JP6577683B2 (ja) * | 2017-09-22 | 2019-09-18 | 旭化成ファーマ株式会社 | 安定性に優れるテリパラチド含有液状医薬組成物 |
CN108159404B (zh) * | 2018-01-05 | 2019-08-27 | 北京博康健基因科技有限公司 | 重组人甲状旁腺激素制剂及其制备方法 |
WO2019220654A1 (ja) * | 2018-05-17 | 2019-11-21 | 旭化成ファーマ株式会社 | N-ホルミルピぺリジン含有量が低減されている、及び/又は、凍結乾燥ケーキの崩潰又は収縮が抑制されている、製剤 |
CN113423383A (zh) * | 2019-02-11 | 2021-09-21 | 阿森迪斯药物骨疾病股份有限公司 | Pth缀合物的液体药物制剂 |
CN112439054B (zh) * | 2019-08-28 | 2023-05-16 | 深圳翰宇药业股份有限公司 | 一种特立帕肽缓释凝胶注射液及其制备方法 |
WO2021144476A1 (en) | 2020-02-18 | 2021-07-22 | Novo Nordisk A/S | Pharmaceutical formulations |
EP4110370A4 (en) * | 2020-03-30 | 2023-06-07 | Sichuan Luzhou Buchang Bio-Pharmaceutical Co., Ltd. | FORMULATIONS OF HUMAN PARATHYROID HORMONE (PTH) AND METHODS OF MANUFACTURE THEREOF |
CN113967249A (zh) * | 2021-12-10 | 2022-01-25 | 深圳先进技术研究院 | 甲状旁腺激素在制备治疗男性抑郁症的药物或保健品中的应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6360940A (ja) † | 1986-09-01 | 1988-03-17 | Toyo Jozo Co Ltd | 白内障の予防または治療剤 |
JP2505812B2 (ja) * | 1987-07-10 | 1996-06-12 | 旭化成工業株式会社 | h―PTH(1―34)凍結乾燥組成物 |
US5059587A (en) * | 1987-08-03 | 1991-10-22 | Toyo Jozo Company, Ltd. | Physiologically active peptide composition for nasal administration |
DE3935738A1 (de) * | 1989-10-27 | 1991-05-08 | Forssmann Wolf Georg | Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff |
GB9020544D0 (en) † | 1990-09-20 | 1990-10-31 | Sandoz Ltd | Improvements in or relating to organic compounds |
US5563122A (en) * | 1991-12-09 | 1996-10-08 | Asahi Kasei Kogyo Kabushiki Kaisha | Stabilized parathyroid hormone composition |
KR100291620B1 (ko) | 1992-09-29 | 2001-10-24 | 추후제출 | 부갑상선호르몬의활성단편의폐를통한전달방법 |
IT1255723B (it) † | 1992-10-09 | 1995-11-13 | Uso di paratormone,suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto pretermine ed in generale per il trattamento della gestazione | |
US5496801A (en) * | 1993-12-23 | 1996-03-05 | Allelix Biopharmaceuticals Inc. | Parathyroid hormone formulation |
DE19538687A1 (de) † | 1995-10-17 | 1997-04-24 | Boehringer Mannheim Gmbh | Stabile pharmazeutische Darreichungsformen enthaltend Parathormon |
-
1998
- 1998-12-04 ZA ZA9811127A patent/ZA9811127B/xx unknown
- 1998-12-04 MY MYPI98005507A patent/MY120063A/en unknown
- 1998-12-07 PT PT98123225T patent/PT920873E/pt unknown
- 1998-12-07 ES ES98123225T patent/ES2215268T3/es not_active Expired - Lifetime
- 1998-12-07 DK DK98123225T patent/DK0920873T3/da active
- 1998-12-07 DE DE69821872T patent/DE69821872T2/de not_active Revoked
- 1998-12-07 DK DK03104219.5T patent/DK1417972T4/en active
- 1998-12-07 EG EG151498A patent/EG23675A/xx active
- 1998-12-07 AR ARP980106213A patent/AR018526A1/es active IP Right Grant
- 1998-12-07 ES ES03104219T patent/ES2405994T5/es not_active Expired - Lifetime
- 1998-12-07 AT AT98123225T patent/ATE260113T1/de not_active IP Right Cessation
- 1998-12-07 EP EP98123225A patent/EP0920873B1/en not_active Revoked
- 1998-12-07 EP EP03104219.5A patent/EP1417972B2/en not_active Expired - Lifetime
- 1998-12-07 PT PT3104219T patent/PT1417972E/pt unknown
- 1998-12-08 PL PL98340902A patent/PL194268B1/pl unknown
- 1998-12-08 IL IL13666298A patent/IL136662A/en not_active IP Right Cessation
- 1998-12-08 CZ CZ20002115A patent/CZ302401B6/cs not_active IP Right Cessation
- 1998-12-08 CA CA002314313A patent/CA2314313C/en not_active Expired - Lifetime
- 1998-12-08 UA UA2000074034A patent/UA72884C2/uk unknown
- 1998-12-08 EA EA200000629A patent/EA004761B1/ru not_active IP Right Cessation
- 1998-12-08 SK SK1532-2000A patent/SK288203B6/sk not_active IP Right Cessation
- 1998-12-08 TR TR2000/02134T patent/TR200002134T2/xx unknown
- 1998-12-08 WO PCT/US1998/026043 patent/WO1999029337A1/en active IP Right Grant
- 1998-12-08 HU HU0004447A patent/HU230784B1/hu unknown
- 1998-12-08 BR BR9813463-9A patent/BR9813463A/pt not_active Application Discontinuation
- 1998-12-08 KR KR10-2000-7006211A patent/KR100482703B1/ko not_active IP Right Cessation
- 1998-12-08 ID IDW20001318A patent/ID27741A/id unknown
- 1998-12-08 NZ NZ505222A patent/NZ505222A/en not_active IP Right Cessation
- 1998-12-08 CN CNB988119641A patent/CN1198644C/zh not_active Ceased
- 1998-12-08 AU AU17177/99A patent/AU759726B2/en not_active Expired
- 1998-12-08 JP JP2000524006A patent/JP4405666B2/ja not_active Expired - Lifetime
- 1998-12-09 PE PE1998001200A patent/PE20000001A1/es not_active IP Right Cessation
- 1998-12-09 TW TW087120429A patent/TW570811B/zh not_active IP Right Cessation
-
1999
- 1999-12-09 HK HK99105809A patent/HK1021798A1/xx not_active IP Right Cessation
-
2000
- 2000-06-08 NO NO20002945A patent/NO327302B1/no not_active IP Right Cessation
-
2013
- 2013-05-17 CY CY20131100405T patent/CY1114000T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1114000T1 (el) | Σταθεροποιημενα διαλυματα τεριπαρατιδης | |
PT1121144E (pt) | Preparados de insulina concentrada estavel para administracao pulmonar | |
DK0999853T3 (da) | Stabiliseret antostofformulering | |
DE3868037D1 (de) | Pharmazeutische zusammensetzung mit verzoegerter wirkstoffabgabe. | |
SE8804629D0 (sv) | New therapeutically active compounds | |
DE3681570D1 (de) | Medizinische einrichtung zur pulsatilen transdermalen verabreichung von biologisch aktiven wirkstoffen. | |
HK1024182A1 (en) | Stabilization of acid sensitive benzimidazols with amino acid/cyclodextrin combinations | |
LV10196A (lv) | Olbaltumviela biologiski aktivais hormons olbaltumvielas iegusanas panemiens farmaceitisks preparats | |
FI960750A0 (fi) | Hermon kasvutekijän farmaseuttiset formulaatiot | |
BR9303469A (pt) | Conjugado de interferon,composto,processo de preparacao de um conjugado de interferon,use e composicoes farmaceuticas | |
TR200402579T4 (tr) | Kristalin monohidrat, bunun imalat yöntemi ve bir ilaç maddesinin imalatında kullanımı | |
IT8720621A0 (it) | Formulazioni di steroide in soluzione acquosa per somministrazione nasale. | |
IT9022045A0 (it) | Procedimento per rivelare la concentrazione di un ingrediente attivo in un sistema acquoso. | |
BR9811094A (pt) | Agente terapêutico para tumores linfáticos | |
IT1314185B1 (it) | Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi | |
PA8451701A1 (es) | Formulacion inyectable transparente de compuesto anestesico | |
ATE228005T1 (de) | Pharmazeutische formulierungen aus corticotropin freisetzenden faktor mit verbesserter stabilitaet in fluessiger form | |
HUP0001739A2 (hu) | Gyógyászati hatóanyagok behatolását fokozó oldószerrendszert tartalmazó helyileg alkalmazott készítmények, valamint pufferolt oldószerrendszer alkalmazása | |
FI884240A (fi) | Menetelmä paikalliseen käyttöön tarkoitetun farmaseuttisen valmisteen valmistamiseksi | |
DK0593562T3 (da) | Topisk præparat indeholdende penciclovir | |
ES2032476T3 (es) | Un procedimiento para preparar nuevos derivados de 2-anilinotiazolina. | |
DE69112028D1 (de) | Arzneizusammensetzungen zur rektalen Verabreichung enthaltend gefriergetrocknetes Calcitonin. |